European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
RegulatoryapprovedICOTYDEPositive
AI Analysis
Summary
Johnson & Johnson received European Commission approval for ICOTYDE (icotrokinra), the first IL-23R targeted oral peptide for first-line systemic treatment of plaque psoriasis, offering skin clearance with a favorable safety profile in once-daily dosing.
Outcome Details
European Commission approval for first-line systemic treatment of plaque psoriasis
Importance:8/10
Sentiment:
0.85
regulatory approvaldermatologyoral treatmentIL-23R inhibitorEurope
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 21, 2026 2:33 PM